144 ·Filed Jun 18, 2026

QURE

uniQure N.V.
NEUTRAL
Impact 3/10
Horizondays Processed3mo ago SEC0001973379-26-000247
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

The sale is pre-scheduled under a 10b5-1 plan, so it does not signal a change in the CEO's view of the company. The filing is routine and consistent with normal equity compensation monetization. Monitor for any subsequent Form 4 filings to confirm execution, but no material read-through for QURE stock.

DirectionNeutral
Confidencehigh
Horizondays
Latest settled — T+20d ⚠ clustered
QURE ▼ -14.97% at T+20d
NEUTRAL call ✗ call lost -14.97% · α vs SPY -15.50% · entry $46.29 → $39.36
Next anchor: T+60d due 18d ago
Latest observation: T+57 -67.21% FF3 residual α
Entry anchored
Jun 17, 07:30 PM ET
via exchange tick
T+1d
-4.10%
call -4.10% · α -3.79%
$44.39
settled 4mo ago
T+5d
+6.07%
call +6.07% · α +7.74%
$49.10
settled 3mo ago
T+20d
-14.97%
call -14.97% · α -15.50%
$39.36
settled 3mo ago
T+60d
—
call — · α —
—
due 18d ago

Price Chart

Loading chart...

Executive Summary

CEO and Managing Director Matthew C. Kapusta filed a Form 144 to sell 164,429 ordinary shares of uniQure N.V., with an estimated market value of approximately $7,044,047. The sale is part of a pre-established 10b5-1 trading plan adopted in October 2025, involving the exercise and sale of vested RSUs and PSUs, as well as stock option exercises. This is a routine, planned sale by a top executive, not a discretionary or opportunistic move.

Key Facts

  • CEO Matthew C. Kapusta filed to sell 164,429 ordinary shares
  • Estimated proceeds of ~$7,044,047 based on filing date price
  • Sale is part of a pre-established 10b5-1 plan adopted in October 2025
  • Shares represent vested RSUs and PSUs, plus stock option exercises
  • Filing date: June 17, 2026; plan adoption date: October 5, 2025

Financial Impact

~$7.0M in planned insider sales, representing ~0.4% of $1.7B market cap

insider holdingsdilution

Risk Factors

  • Insider selling, even under a plan, can create short-term overhang
  • If the CEO accelerates sales beyond the plan, it would be a bearish signal

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
76% bullish (21 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001973379-26-000247
Document: 0001973379-26-000247-index.html0001973379-26-000247
Document: 0001973379-26-000247.txt0001973379-26-000247
32 reports for QURE
Performance horizon
67% Hit rate 6 of 9 directional calls best @ T+20▲ +27.15%Jul 29, 2026
Filters
Rows
Reports for QURE — sortable, filterable
TypeNow
Sep 2, 2026
4w ago
8-K
BULLISH ★ 7/10
$46.23 $44.47▼ −3.81%▼ −2.85%$23.46 (−49.25%)
Jul 29, 2026
9w ago
8-K
BULLISH ★ 8/10
$40.07 $44.24▲ +10.41%▲ +4.88%$23.46 (−41.45%)
Jul 7, 2026
12w ago
Insider Cluster
BEARISH ★ 5/10
$41.41 $41.52▼ −0.27%▲ +0.29%$23.46 (+43.35%)
Jul 2, 2026
13w ago
Insider Cluster
BEARISH ★ 4/10
$41.81 $44.48▼ −6.39%▼ −5.46%$23.46 (+43.89%)
Jul 2, 2026
13w ago
Insider Cluster
MIXED ★ 5/10
$41.81 $44.48▲ +6.39%▲ +5.46%$23.46 (−43.89%)
Jul 2, 2026
13w ago
144
NEUTRAL ★ 2/10
$41.81 $44.48▲ +6.39%▲ +5.46%$23.46 (−43.89%)
Jun 30, 2026
13w ago
144
NEUTRAL ★ 2/10
$45.17 $41.41▼ −8.32%▼ −8.59%$23.46 (−48.06%)
Jun 25, 2026
14w ago
144
BEARISH ★ 5/10
$47.51 $41.81▲ +12.00%▲ +14.16%$23.46 (+50.62%)
Jun 24, 2026
14w ago
424B5
MIXED ★ 6/10
$49.10 $45.17▼ −8.00%▼ −9.56%$23.46 (−52.22%)
Jun 24, 2026
14w ago
144
NEUTRAL ★ 2/10
$49.10 $45.17▼ −8.00%▼ −9.56%$23.46 (−52.22%)
Showing 10 of 32

US Market Status

Market Closed — Opens Mon (64h 21m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access